Vemurafenib and dabrafenib were the first selective BRAF inhibitors (BRAFi) approved for clinical use in 2011 and 2013, respectively, and have clinical response rates of about 50% in BRAF-mutant melanoma [2]. Here, BRAF is linked to melanoma.